Reviewer's report

Title: Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: A retrospective, multicenter, comparative study

Version: 5, Date: 18 April 2014

Reviewer: Rufino Suilva

Reviewer's report:

Minor Essential Revisions

This is an interesting manuscript describing the 1-year results of a retrospective, multicentre study comparing Bevacizumab and ranibizumab in the treatment of m-CNV.

Only a few suggestions are done:
1- Regarding different OCTs used, a potential option could be an adjustment of values of OCT measurements
2- Results at 4 years are already published, comparing bevacizumab and ranibizumab (Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Ruiz Moreno et al. Br J Ophthalmol doi:10.1136/bjophthalmol-2012-302973). Please include in references and discussion.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I am member of advisory board for:
THEA, Novartis, Alimera, Bayer, Allergan